[HTML][HTML] Alzheimer's disease THErapy with NEuroaid (ATHENE): A randomized double-blind delayed-start trial
Objectives Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial.
CLH Chen, Q Lu, RB Moorakonda… - Journal of the …, 2021 - europepmc.org
Objectives Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
[HTML][HTML] Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial
CLH Chen, Q Lu, RB Moorakonda, N Kandiah… - Journal of the American …, 2022 - jamda.com
Objectives Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial
CLH Chen, Q Lu, RB Moorakonda, N Kandiah, BY Tan… - 2022 - pubmed.ncbi.nlm.nih.gov
Objectives Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …
Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to …